Heart Failure
Microaxial Flow Pumps in Heart Failure-Related Cardiogenic Shock — State-of-the-Art Review
- Authors: Review authors
- Journal / date: Journal of Cardiac Failure, 2026
- DOI / URL: 10.1016/j.cardfail.2026.04.001 | PMID 42097529
- Source basis: Abstract only
- Study type: State-of-the-art review
- Scope: Use of microaxial flow pumps (Impella CP, 5.5) in HF-related cardiogenic shock (HF-CS), distinct from AMI-CS
- Key clinical points:
- HF-CS is now the leading etiology of cardiogenic shock — distinct pathophysiology from AMI-CS.
- DanGer Shock showed Impella CP mortality benefit in AMI-CS but extrapolation to HF-CS is not warranted.
- PAC-guided hemodynamic profiling is the recommended backbone for initial device selection, escalation, and weaning.
- Surgically implanted axillary Impella 5.5 enables higher flow, longer duration, ambulation — supports bridge-to-decision and bridge-to-replacement pathways.
- Observational data favor early shock recognition and prompt support over watchful waiting.
- Why it matters (clinical takeaway):
- Practical roadmap for HF-CS device selection in a literature dominated by AMI-CS trials.
- Anchors PAC use back into shock-team workflows — directly relevant to ICU and CICU decisions.
- Read alongside the Intermacs Impella → LVAD outcomes paper (2026-05_intermacs-impella-lvad-ai-rhf.md) to weigh durable-implant downstream risks when planning preop mAFP duration.
- Caveats / limitations: Review, not new primary data. Most mAFP evidence in HF-CS is observational/registry.
- Referenced trials pulled forward: DanGer Shock — to add to trials/ on next pass.